▼ FY 2025 Summary Analysis
Annual report ending Dec 31, 2025Overview and Growth
Immix Biopharma, Inc. recorded fiscal 2025 net loss of $29.44M. The company reported diluted EPS of -$0.89, adding a shareholder-level measure to the absolute income figures considered below. The diluted weighted-average share count was 32.97M, linking total earnings with the per-share result received by shareholders. Compared with 28.29M diluted shares in fiscal 2024, the current 32.97M base was 16.5% higher. Total assets stood at $104.84M, showing the scale of resources supporting revenue, earnings, liquidity, and financing.Profitability
The company recorded an operating loss of $29.96M after the reported operating expense base. The bottom-line result was a net loss of $29.44M after operating, financing, tax, and other recognized items. EBITDA was negative $29.71M, showing a deficit before interest, taxes, depreciation, and amortization. The pretax result was a loss of $29.40M, establishing the deficit before tax effects. The reported income-tax provision was $37.72K, the amount recognized between pretax income and the final net-income result. The net loss equaled 31.4% of period-end equity, showing the deficit relative to book capital. The loss-to-assets relationship was 28.1%, placing the bottom-line deficit against the company’s resource base. The net loss widened to $29.44M from $21.61M in fiscal 2024.Liquidity and Capital Structure
The company held $104.84M of assets against $11.04M of liabilities and $93.80M of equity, revealing how the asset base was financed. Current assets were $101.24M against $10.11M of current liabilities, framing the resources and obligations classified within the near-term balance-sheet horizon. The current ratio was 10.01x, with current assets exceeding current liabilities and providing a short-term liquidity cushion. Cash and equivalents totaled $93.93M, identifying the most liquid reported component available within the broader current-asset balance. Measured only with cash and equivalents, coverage of current liabilities was 929.0%, excluding receivables and other current assets. Book equity represented 89.5% of total assets, quantifying the balance-sheet share supported by shareholder capital. The liabilities-to-assets relationship was 10.5%, placing reported obligations against the full positive asset balance. Measured against total assets, cash and equivalents represented 89.6%, a balance-sheet composition measure rather than a liquidity forecast. The asset base changed 356.9% from $22.95M in fiscal 2024, leaving current total assets higher year over year. Reported equity changed 607.8% from $13.25M in fiscal 2024, placing the current capital base higher year over year. The reported cash balance changed 431.2% from $17.68M in fiscal 2024, ending higher year over year.Cash Flow and Earnings Quality
Operating activities used $23.93M of cash, resulting in an operating cash outflow for the year. Capital spending of $732.92K added to the period’s operating cash use, reinforcing the overall cash deficit after investment for the year. The company recorded a $24.66M cash deficit after capital spending for the period. Relative to total assets, the post-investment cash deficit measured 23.5%. Compared with a $14.60M operating cash outflow in fiscal 2024, the current outflow increased to $23.93M.
Based on the annual report for the fiscal year ending Dec 31, 2025.
Analysis generated .
Fundamentals Hub